Evidence map›Paper›PMID 41074029›Full record

ArticleJournal of nanobiotechnology2025

Outer membrane vesicles-based nano-regulator for cancer immunotherapy by modulating neutrophils N1 polarization and hitchhiking delivery.

Xiaoning Liu, Qun Niu, Haoxiang Yang, Tongyao Du, Yichen Liu, Hengqi Zhou, Shuqi Wang, Lingli Shen, Xuannian Wang, Gaiping Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoning Liu *College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Qun Niu *College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Haoxiang YangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Tongyao DuCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Yichen LiuCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Hengqi ZhouCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Shuqi WangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Lingli ShenCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Xuannian WangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China.
Gaiping ZhangCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China. zhanggaiping@henau.edu.cn.
Hua HeCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Agricultural University, Zhengzhou, 450046, China. hhe@henau.edu.cn.

Funding

Key Projects of Science and Technology of Henan Province 221100110600National Natural Science Foundation of China 32473118the Young TopNotch Talents Foundation of Henan Agricultural University 30500737
6 · The paper itself

Abstract

Efficient eradication of cancer cells and enhanced tumor accumulation of drug via immune cells represent promising strategies for cancer treatment, yet they remain significant challenges. Inspired by neutrophils (NEs), we designed a novel nano-regulator (OMV@PCB NPs) to improve cancer therapy through polarizing NEs into anti-tumor N1 phenotype and photodynamic therapy (PDT)-assisted NEs hitchhiking delivery. OMV@PCB NPs were constructed by encapsulating Ce6 and SB525334 (TGF-β inhibitor) within PLGA nanoparticles, which were subsequently camouflaged with bacteria outer membrane vesicles (OMVs). Beyond inducing ROS generation under light irradiation to kill tumor cells, OMV@PCB NPs could effectively hitchhike NEs to enhance tumor accumulation based on PDT-assisted NEs recruitment. Encouragingly, SB525334, a TGF-β inhibitor in OMV@PCB NPs, could significantly polarize NEs into anti-tumor N1 phenotype, which could not only promote neutrophil elastase (ELANE) release to selectively eliminate cancer cells, but also elevate anticancer immunity by reversing the immunosuppressive tumor microenvironment, thereby achieving effective immuno-photodynamic therapy against tumor growth. This study offers a prospective avenue for enhancing cancer therapy.

Indexed as

ImmunotherapyNanoparticlesNeoplasmsNeutrophilsAnimalsCell Line, TumorChlorophyllidesFemaleHumansMiceMice, Inbred BALB CPhotochemotherapyPolylactic Acid-Polyglycolic Acid CopolymerTransforming Growth Factor betaTumor MicroenvironmentChlorophyllidesphytochlorinPolylactic Acid-Polyglycolic Acid CopolymerTransforming Growth Factor betaCancer immunotherapyHitchhiking deliveryNeutrophil polarizationOuter membrane vesicles (OMVs)TGF-β inhibitor

Identifiers

PMID41074029
PMCPMC12514824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.